5-nitro-2-propyloxy-benzylalcohol | 209402-08-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 5-nitro-2-propyloxy-benzylalcohol
• 英文别名: (5-nitro-2-propoxyphenyl)methanol
• CAS: 209402-08-4
• 化学式: C₁₀H₁₃NO₄
• 分子量: 211.218
• InChiKey: NXKKMYMYNHVSPE-UHFFFAOYSA-N

物化性质

• 沸点：
  380.168±27.00 °C(Press: 760.00 Torr)(predicted)
• 密度：
  1.227±0.06 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  75.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  5-nitro-2-propyloxy-benzylalcohol 在 palladium on activated charcoal 盐酸 、 氢气 作用下， 以 甲醇 为溶剂， 反应 17.0h， 生成 2-(5-Amino-2-propoxy-benzyl)-benzene-1,4-diol
  参考文献：
  名称：

  Molecular receptor for binding quaternary ammonium salts and a large anion effect on the complexation

  摘要：

  An acyclic receptor 1 with a binding cavity surrounded by electron-rich aryl surfaces has been synthesized for binding quaternary ammonium salts through cation-pi interactions. The association constants of the receptor 1 with salts in CDCl3 depend on the anions due to the hydrogen bonds between the exchangeable protons in the receptor 1 and anions. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(98)00615-7
• 作为产物：
  描述：

  2-羟基-5-硝基苄溴 在 potassium carbonate 、 calcium carbonate 作用下， 以 丙酮 为溶剂， 生成 5-nitro-2-propyloxy-benzylalcohol
  参考文献：
  名称：

  Molecular receptor for binding quaternary ammonium salts and a large anion effect on the complexation

  摘要：

  An acyclic receptor 1 with a binding cavity surrounded by electron-rich aryl surfaces has been synthesized for binding quaternary ammonium salts through cation-pi interactions. The association constants of the receptor 1 with salts in CDCl3 depend on the anions due to the hydrogen bonds between the exchangeable protons in the receptor 1 and anions. (C) 1998 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0040-4039(98)00615-7

文献信息

• Bicyclic compositions and methods for modulating a kinase cascade
  申请人：Hangauer David G.

  公开号：US20080004241A1

  公开（公告）日：2008-01-03

  The invention relates to compounds and methods for modulating one or more components of a kinase cascade.

  该发明涉及化合物和方法，用于调节激酶级联中的一个或多个组分。
• Protein kinase and phosphatase inhibitors and methods for designing them
  申请人：——

  公开号：US20030166615A1

  公开（公告）日：2003-09-04

  The present invention provides a method for identifying inhibitors of protein kinases and/or protein phosphatases. Methods are also provided for inhibiting protein kinase and/or protein phosphatase activity. Specific non-peptide protein tyrosine kinase and/or protein phosphatase inhibitors are provided. The protein kinase or protein phosphatase inhibitors of the present invention may be used to treat a number of conditions in patients, including cancer, psoriasis, arthrosclerosis, immune system activity, Type II diabetes, and obesity.

  本发明提供了一种识别蛋白激酶和/或蛋白磷酸酶抑制剂的方法。还提供了用于抑制蛋白激酶和/或蛋白磷酸酶活性的方法。具体的非肽蛋白酪氨酸激酶和/或蛋白磷酸酶抑制剂也被提供。本发明的蛋白激酶或蛋白磷酸酶抑制剂可用于治疗患者的多种疾病，包括癌症、银屑病、动脉粥样硬化、免疫系统活性、2型糖尿病和肥胖症。
• OXYGEN LINKED PYRIMIDINE DERIVATIVES
  申请人：Blanchard Stephanie

  公开号：US20120196855A1

  公开（公告）日：2012-08-02

  The present invention relates to pyrimidine compounds that are useful as anti-proliferative agents. More particularly, the present invention relates to oxygen linked and substituted pyrimidine compounds, methods for their preparation, pharmaceutical compositions containing these compounds and uses of these compounds in the treatment of proliferative disorders. These compounds may be useful as medicaments for the treatment of a number of proliferative disorders including tumours and cancers as well as other disorders or conditions related to or associated with kinases.

  本发明涉及嘧啶化合物，其作为抗增殖剂具有用处。更具体地说，本发明涉及氧连接和取代的嘧啶化合物，其制备方法，含有这些化合物的制药组合物以及这些化合物在治疗增殖性疾病方面的用途。这些化合物可用作治疗许多增殖性疾病，包括肿瘤和癌症以及与激酶相关或相关的其他疾病或病况的药物。
• [EN] PROTEIN KINASE AND PHOSPHATASE INHIBITORS, METHODS FOR DESIGNING THEM, AND METHODS OF USING THEM<br/>[FR] INHIBITEURS DE PROTEINES KINASES ET DE PROTEINES PHOSPHATASES, METHODES D'IDENTIFICATION ET METHODES D'UTILISATION ASSOCIEES
  申请人：UNIV NEW YORK STATE RES FOUND

  公开号：WO2003035621A1

  公开（公告）日：2003-05-01

  The present invention provides a method for identifying inhibitors of protein kinases and/or protein phosphatases. Methods are also provided for inhibiting protein kinase and/or protein phosphatase activity. Specific non-peptide protein tyrosine kinase and/or protein phosphatase inhibitors are provided. The protein kinase or protein phosphatase inhibitors of the present invention may be used to treat a number of conditions in patients, including cancer, psoriasis, arthrosclerosis, immune system activity, diabetes, or obesity. In addition, the present invention provides a method for protecting against or treating hearing loss in a subject. This method involves administering an effective amount of a protein tyrosine kinase inhibitor to the subject to protect against or to treat hearing loss.

  本发明提供了一种识别蛋白激酶和/或蛋白磷酸酶抑制剂的方法。还提供了抑制蛋白激酶和/或蛋白磷酸酶活性的方法。提供了特定的非肽蛋白酪氨酸激酶和/或蛋白磷酸酶抑制剂。本发明的蛋白激酶或蛋白磷酸酶抑制剂可用于治疗患者的多种病症，包括癌症、牛皮癣、动脉硬化、免疫系统活动、糖尿病或肥胖症。此外，本发明提供了一种保护或治疗受试者听力损失的方法。该方法涉及向受试者投与有效量的蛋白酪氨酸激酶抑制剂以保护或治疗听力损失。
• Protection against and treatment of hearing loss
  申请人：Nicotera Thomas

  公开号：US20060172971A1

  公开（公告）日：2006-08-03

  The present invention provides a method for protecting against or treating hearing loss in a subject. This method involves administering an effective amount of a protein tyrosine kinase inhibitor to the subject to protect against or to treat hearing loss.

  本发明提供了一种用于保护或治疗受试者听力丧失的方法。该方法涉及向受试者施用有效剂量的蛋白酪氨酸激酶抑制剂，以保护或治疗听力丧失。